DE602005010676D1 - Behandlung von druckgeschwüren - Google Patents

Behandlung von druckgeschwüren

Info

Publication number
DE602005010676D1
DE602005010676D1 DE602005010676T DE602005010676T DE602005010676D1 DE 602005010676 D1 DE602005010676 D1 DE 602005010676D1 DE 602005010676 T DE602005010676 T DE 602005010676T DE 602005010676 T DE602005010676 T DE 602005010676T DE 602005010676 D1 DE602005010676 D1 DE 602005010676D1
Authority
DE
Germany
Prior art keywords
treatment
pressure
pressure treatments
pressure sore
sore
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005010676T
Other languages
English (en)
Inventor
Eric R First
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of DE602005010676D1 publication Critical patent/DE602005010676D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
DE602005010676T 2004-03-31 2005-03-28 Behandlung von druckgeschwüren Active DE602005010676D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/814,764 US20050220821A1 (en) 2004-03-31 2004-03-31 Pressure sore treatment
PCT/US2005/010461 WO2005097178A1 (en) 2004-03-31 2005-03-28 Pressure sore treatment

Publications (1)

Publication Number Publication Date
DE602005010676D1 true DE602005010676D1 (de) 2008-12-11

Family

ID=34964467

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005010676T Active DE602005010676D1 (de) 2004-03-31 2005-03-28 Behandlung von druckgeschwüren

Country Status (10)

Country Link
US (2) US20050220821A1 (de)
EP (1) EP1729796B1 (de)
JP (2) JP2007531747A (de)
AT (1) ATE412424T1 (de)
AU (1) AU2005231360B2 (de)
BR (1) BRPI0509478A (de)
CA (1) CA2561588C (de)
DE (1) DE602005010676D1 (de)
DK (1) DK1729796T3 (de)
WO (1) WO2005097178A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
FR2879462B1 (fr) * 2004-12-21 2008-12-26 Sod Conseils Rech Applic Utilisation de toxine botulique pour une insensibilisation locale prolongee
US20070238630A1 (en) * 2006-03-29 2007-10-11 Phillips Douglas H Subcutaneous skin cleanser
WO2013142755A1 (en) * 2012-03-22 2013-09-26 Revance Therapeutics, Inc. Method of treatment of wrinkles using topical chemodenervating agents

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4330527A (en) * 1979-11-13 1982-05-18 Teruo Arima Wound treatment agent
US4805605A (en) * 1988-01-11 1989-02-21 Glassman Medical Products, Inc. Abduction pillow
US5393792A (en) * 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
JPH07118165A (ja) * 1993-10-22 1995-05-09 Asahi Chem Ind Co Ltd カルシトニン遺伝子関連ペプチド類を含有する経皮吸収組成物
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
DK0758900T3 (da) * 1994-05-09 2002-07-29 William J Binder Botulinumtoksin til reduktion af migræne-hovedpinesmerter
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
JPH0840926A (ja) * 1994-08-03 1996-02-13 Yakurigaku Chuo Kenkyusho:Kk 皮膚潰瘍治療薬
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
DK0773788T3 (da) * 1995-06-06 2003-09-01 Allergan Inc Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner
US5851522A (en) * 1995-06-07 1998-12-22 Trustees Of Tufts College Enhancing keratinocyte migration
US6670337B1 (en) * 1998-01-29 2003-12-30 Yeda Reaearch And Development Co., Ltd. Facilitation of wound healing with CM101/GBS toxin
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
JP4726296B2 (ja) * 1998-02-27 2011-07-20 インスティチュート ストローマン アーゲー 創傷治癒のためのマトリックスタンパク質組成物
US6524568B2 (en) * 1998-06-22 2003-02-25 Cytomedix, Inc. Enriched platelet wound healant
AU1706400A (en) * 1998-10-27 2000-05-15 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6429189B1 (en) * 1999-12-10 2002-08-06 Botulinum Toxin Research Associates, Inc. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
WO2002012479A2 (en) * 2000-08-07 2002-02-14 Zymogenetics, Inc. Zcys9: a member of the cystatin superfamily
JP4096115B2 (ja) * 2000-08-10 2008-06-04 輝夫 西田 皮膚創傷治癒促進剤
US6678651B2 (en) * 2000-09-15 2004-01-13 Mindspeed Technologies, Inc. Short-term enhancement in CELP speech coding
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US7026462B2 (en) * 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US20020192239A1 (en) * 2001-01-09 2002-12-19 Borodic Gary E. Use of botulinum toxin for the treatment of chronic facial pain
US7108683B2 (en) * 2001-04-30 2006-09-19 Kci Licensing, Inc Wound therapy and tissue management system and method with fluid differentiation
WO2003011333A1 (en) 2001-07-27 2003-02-13 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Botulinum toxin in the treatment or prevention of acne
EP1425027A4 (de) * 2001-08-16 2008-02-13 Thomas M Hnat Verfahren und zusammensetzung zur behandlung von wunden und verbrennungen
US20030224019A1 (en) * 2002-03-01 2003-12-04 O'brien Christopher Methods of treating nerve entrapment syndromes
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
DE60326370D1 (de) * 2002-08-12 2009-04-09 Actavis Group Hf Verwendung von cgrp-antagonisten-verbindungen zur behandlung von psoriasis
US20040167223A1 (en) * 2002-09-03 2004-08-26 Popp Karl F. Topical antibacterial formulations
WO2004033668A2 (en) * 2002-10-10 2004-04-22 Diversa Corporation Proteases, nucleic acids encoding them and methods for making and using them
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
AU2005218539A1 (en) * 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
LT2985039T (lt) * 2004-03-03 2018-11-12 Revance Therapeutics, Inc. Botulino toksinų vietinis taikymas ir jų įvedimas per odą
WO2005110417A1 (en) * 2004-05-07 2005-11-24 Phytotox Limited Phycotoxins and uses thereof
US7179474B2 (en) * 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US20060058238A1 (en) * 2004-09-15 2006-03-16 Lee Laurent-Applegate Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
US20060067950A1 (en) * 2004-09-27 2006-03-30 Merz Pharma Gmbh & Co. Kgaa Clostridial neurotoxins for use in wound healing
EP2210635A3 (de) * 2006-02-09 2012-11-07 Aderans Research Institute, Inc. Vorrichtung zur Abgabe von Flüssigkeit und Material an eine Person
US9283217B2 (en) * 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Also Published As

Publication number Publication date
ATE412424T1 (de) 2008-11-15
JP2013075902A (ja) 2013-04-25
JP2007531747A (ja) 2007-11-08
EP1729796B1 (de) 2008-10-29
EP1729796A1 (de) 2006-12-13
AU2005231360B2 (en) 2009-10-29
JP5674164B2 (ja) 2015-02-25
CA2561588A1 (en) 2005-10-20
AU2005231360A1 (en) 2005-10-20
US8865177B2 (en) 2014-10-21
WO2005097178A1 (en) 2005-10-20
DK1729796T3 (da) 2009-01-19
CA2561588C (en) 2012-08-28
US20080050404A1 (en) 2008-02-28
BRPI0509478A (pt) 2007-09-11
US20050220821A1 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
ATE462443T1 (de) Dehnungsstreifenbehandlung mit botulinumtoxin
TW200503751A (en) Methods for treating sinus headache
DK2154151T3 (da) Clostridiumtoksinaktiverbare clostridiumtoksiner
DK2282766T3 (da) Suturlinie-indgivelsesteknik med anvendelse af botulinumtoksiner
MXPA03002576A (es) Metodos para tratar lesiones musculares.
BR0309888A (pt) Tratamento intracraniano de distúrbios neuropsiquiátricos por neurotoxinas clostridiais tal como a toxina da botulina
DE60310400D1 (de) Botulinustoxine zur behandlung von priapismus
AR065033A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
PT1492561E (pt) Metodo para tratar disturbios da glandula mamaria
ATE255418T1 (de) Neurotoxine zur behandlung von pankreatischen krankheiten
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
BRPI0416268A (pt) composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla
MX2022010186A (es) Neurotoxinas botulinas para uso en terapia.
WO2008090287A3 (fr) Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida
DE602005010676D1 (de) Behandlung von druckgeschwüren
BRPI0514836A (pt) uso de toxina botulìnica para tratamento de uma deformidade da nádega
MX2021007076A (es) Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
EA200802136A1 (ru) Лечение меланомы
DK1368023T3 (da) Anvendelse af buprenoprphin til behandling af urininkontinens
BRPI0514895A (pt) tratamento de estria
DE602006021048D1 (de) Behandlung von akutem nierenversagen mit löslichem thrombomodulin
BR112021004776A2 (pt) Métodos para tratamento de hipertrofia do músculo masseter
AR060934A1 (es) Uso de un activador de plasminogeno para la manufactura de un medicamento para el tratamiento de tromboembolismo venoso
RU2007139974A (ru) Способ лечения атопического дерматита
EA200801669A1 (ru) Способ лечения тиннитуса

Legal Events

Date Code Title Description
8364 No opposition during term of opposition